New drug combo shows promise for kids with transplant complication
NCT ID NCT03774082
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tested adding the drug ruxolitinib to standard steroid treatment for children aged 28 days to under 18 years who had moderate to severe chronic graft-versus-host disease (cGvHD) after a stem cell transplant. cGvHD is a condition where donor immune cells attack the child's body. The main goal was to see how many children had a complete or partial response by 7 months. The study enrolled 46 participants and measured response rates, drug levels, and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
São Paulo, 04039 001, Brazil
-
Novartis Investigative Site
Toronto, Ontario, M5G 1X8, Canada
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Tamil Nadu, Chennai, 600035, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
Bangalore, 560099, India
-
Novartis Investigative Site
Delhi, 110 085, India
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 466 8560, Japan
-
Novartis Investigative Site
Saitama, 330 8777, Japan
-
Novartis Investigative Site
Saint Petersburg, 197022, Russia
-
Novartis Investigative Site
Bratislava, 833 40, Slovakia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Zurich, CH - 8032, Switzerland
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Adana, 1330, Turkey (Türkiye)
-
Novartis Investigative Site
Antalya, 07000, Turkey (Türkiye)
-
Novartis Investigative Site
Antalya, 07070, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.